Key Findings
The Center for International Blood and Marrow Transplant Research (CIBMTR) provided invaluable insights into the incidence and management of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) following CAR-T cell therapy. Their real-world data analysis included 927 patients with B-cell malignancies treated with either axicabtagene ciloleucel (axi-cel) or brexucabtagene autoleucel (brexu-cel) across 87 centers in the United States.
Technical / Clinical Details
Axicabtagene ciloleucel and brexucabtagene autoleucel are both CD19-targeted autologous CAR-T cell therapies approved for the treatment of relapsed or refractory B-cell malignancies, such as diffuse large B-cell lymphoma and mantle cell lymphoma. While these therapies demonstrate high response rates, they are associated with severe adverse events like CRS and ICANS. CRS is a systemic inflammatory response triggered by the activation of CAR-T cells and the subsequent release of large quantities of inflammatory cytokines, leading to symptoms such as fever, hypotension, and organ dysfunction. ICANS involves neurological impairment, manifesting as delirium, seizures, and aphasia.
This study meticulously investigated the real-world incidence of these adverse events and the patterns of prophylactic and therapeutic interventions applied to manage them. The findings reveal how the incidence rates reported in controlled clinical trials translate to a real-world environment and how CRS and ICANS are managed across diverse facilities and patient populations. This large-scale, real-world data provides crucial information that can contribute to optimizing standard treatment protocols and developing risk stratification strategies.
Background & Context
CAR-T cell therapy has revolutionized hematologic cancer treatment, but its complex safety profile remains a major challenge in its implementation and management. While clinical trials involve stringent patient selection and controlled environments, real-world settings include a more diverse patient population with varied ages, comorbidities, and treatment histories, potentially leading to different incidence rates and severities of adverse events. Large registry data, such as that collected by CIBMTR, are essential for bridging these real-world gaps and providing invaluable information to healthcare professionals for safely and effectively administering CAR-T therapy. Specifically, the appropriate management of CRS and ICANS is critical for the broader adoption of CAR-T therapy and improving patient outcomes.
Strategic Significance & Outlook
This real-world data analysis by CIBMTR is extremely important for deepening the understanding of CAR-T cell therapy’s safety profile. The insights gained will aid in establishing best practices for the prevention, early detection, and treatment of CRS and ICANS following CD19-targeted CAR-T cell therapies, including axi-cel and brexu-cel. In the future, this data is expected to lead to the development of more personalized risk assessment models and novel therapeutic interventions to reduce the risk of adverse events, thereby further improving the safety and efficacy of CAR-T cell therapy. This continuous safety monitoring and data analysis form the foundation for the long-term success of CAR-T therapy and its expanded application to a wider range of diseases.
Source: https://pubmed.ncbi.nlm.nih.gov/42537846/
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments